WuXi Biologics Named Industry and Regional ESG Top Performer by Morningstar Sustainalytics for Fifth Year
Shanghai, Feb. 12, 2025 – WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has once again been recognized as a top-ranked company in environmental, social, and governance (ESG) performance by Morningstar Sustainalytics. This marks the fifth consecutive year the company has secured a top spot in ESG Risk Ratings, ranking among the top 1% of pharmaceutical firms evaluated.
Sustainalytics, a global leader in ESG research and ratings, assesses over 15,000 companies across 42 industries, awarding Top-Rated Badges to those demonstrating outstanding ESG performance. WuXi Biologics’ continued recognition underscores its leadership in sustainable business practices and innovation in the biopharmaceutical sector.
“We are honored to receive this recognition from Morningstar Sustainalytics once again,” said Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee. “This reflects our unwavering commitment to sustainability and responsible business practices. As a pioneer in Green CRDMO, we not only drive our own ESG initiatives but also empower partners worldwide to meet their sustainability goals.”
WuXi Biologics’ ESG achievements have garnered widespread industry recognition. The company was featured in the UN Global Compact’s 20 Case Examples of Sustainable Development and earned an MSCI AAA Rating. It has been included in the Dow Jones Sustainability Indices for two consecutive years, received the Platinum Medal from EcoVadis, and secured high rankings in CDP’s Climate Change and Water Security assessments. Additionally, WuXi Biologics is a constituent of the FTSE4Good Index Series and the Hang Seng ESG 50 Index.
With its strong ESG strategy and commitment to innovation, WuXi Biologics continues to set industry benchmarks in sustainable biopharmaceutical development.
www.wuxibiologics.com.
-asianewstoday.com
